These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 19146644)

  • 21. Immunosuppressive therapies in myasthenia gravis.
    Sanders DB; Evoli A
    Autoimmunity; 2010 Aug; 43(5-6):428-35. PubMed ID: 20166870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
    Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
    J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
    Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
    Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of myasthenia gravis.
    Arora Y; Li Y
    Hosp Pract (1995); 2013; 41(4):40-50. PubMed ID: 24145588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate mofetil and myasthenia gravis.
    Ciafaloni E
    Lupus; 2005; 14 Suppl 1():s46-9. PubMed ID: 15803932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis.
    Roda RH; Doherty L; Corse AM
    Neuromuscul Disord; 2019 Jul; 29(7):554-561. PubMed ID: 31296355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical treatment options for ocular myasthenia gravis.
    Antonio-Santos AA; Eggenberger ER
    Curr Opin Ophthalmol; 2008 Nov; 19(6):468-78. PubMed ID: 18854691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of myasthenia gravis.
    Saperstein DS; Barohn RJ
    Semin Neurol; 2004 Mar; 24(1):41-8. PubMed ID: 15229791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of myasthenia gravis with intravenous immunoglobulin G (IVIG)].
    Lavrnić DB; Stojanović V; Marinković Z; Pavlović S; Vidaković A; Apostolski S
    Srp Arh Celok Lek; 1995; 123(5-6):146-8. PubMed ID: 17974459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refractory myasthenia gravis successfully treated with ofatumumab.
    Waters MJ; Field D; Ravindran J
    Muscle Nerve; 2019 Dec; 60(6):E45-E47. PubMed ID: 31509254
    [No Abstract]   [Full Text] [Related]  

  • 31. [A case of refractory generalized myasthenia gravis with anti-acetylcholine receptor antibodies treated with rituximab].
    Hayashi R; Tahara M; Oeda T; Konishi T; Sawada H
    Rinsho Shinkeigaku; 2015; 55(4):227-32. PubMed ID: 25904250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Myasthenia in elderly patients: a series of 23 cases].
    Durand F; Camdessanché JP; Jomir L; Antoine JC; Cathébras P
    Rev Med Interne; 2005 Dec; 26(12):924-30. PubMed ID: 16229927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
    Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
    J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis.
    Cocito D; Grimaldi S; Paolasso I; Falcone Y; Antonini G; Benedetti L; Briani C; Fazio R; Jann S; Matà S; Sabatelli M; Nobile-Orazio E;
    Eur J Neurol; 2011 Dec; 18(12):1417-21. PubMed ID: 21819489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Actual aspects of myasthenia gravis treatment].
    Czapliński A; Radziwiłł AJ; Steck AJ
    Pol Merkur Lekarski; 2003 Mar; 14(81):256-60. PubMed ID: 12914109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH; Prose NS; Ware RE; Hall RP
    Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab treatment of myasthenia gravis: A systematic review.
    Tandan R; Hehir MK; Waheed W; Howard DB
    Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment strategies for myasthenia gravis.
    Díaz-Manera J; Rojas-García R; Illa I
    Expert Opin Pharmacother; 2009 Jun; 10(8):1329-42. PubMed ID: 19445561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to therapy in myasthenia gravis with anti-MuSK antibodies.
    Evoli A; Bianchi MR; Riso R; Minicuci GM; Batocchi AP; Servidei S; Scuderi F; Bartoccioni E
    Ann N Y Acad Sci; 2008; 1132():76-83. PubMed ID: 18567856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide.
    Drachman DB; Jones RJ; Brodsky RA
    Ann Neurol; 2003 Jan; 53(1):29-34. PubMed ID: 12509845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.